Biotechnology

Carl Icahn Ends Second Proxy Fight with Illumina (ILMN) Board

Activist investor Carl Icahn spares Illumina a second proxy contest, but continues lawsuit, leaving retail investors curious about board dynamics and legal implications.

Biopharmaceutical M&A Surge Revitalizes Industry

Uncover the latest M&A trends in biopharma, featuring big moves by BMY, MRK, BSX, and JNJ in a market ripe with opportunity.

Eli Lilly's Zepbound Shows Short-Lived Weight Loss Benefits

Uncover key investment insights in the dynamic obesity drug market. Discover growth, value, and momentum strategies in this evolving healthcare sector.

AbbVie Stock in Focus with Strategic Cerevel Acquisition

AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.

Gilead Sciences Marks Two Years of Robust Growth

Gilead Sciences reports robust Q3 growth, driven by oncology and HIV treatments, highlighting a solid pipeline and strategic expansion in global markets. The company is poised for a busy 2024 with multiple clinical updates.

Exact Sciences Records Stellar Q3 2023 Results

Exact Sciences showcases robust Q3 results, marking a turning point with increased revenue, diversified streams, and an upward trajectory.

EXACT Sciences Gears Up for Earnings Reveal

EXACT Sciences eyes a pivotal moment with its upcoming Q3 earnings report. The firm excels in ESG ratings and revenue, but operational costs raise questions.

Who is Vivek Ramaswamy and What is His Net Worth?

Vivek Ramaswamy is a new force in US politics, having risen to second place in the race for the Republican nomination. But who is Vivek Ramaswamy and how did he make his millions?

Are Biotech Penny Stocks Worth Investing In?

What can biotech penny stocks do for you? While investors might be attracted by the potential for outsize returns, there are serious risks to consider before throwing weight behind these cheap stocks.

Understanding Drug Development and Approval Process

New drugs and treatments have to undergo a long process of development, clinical trials and FDA approvals before they can start bringing in revenue for pharma and biotech companies.

An Introduction to Biopharma: A New Era in Medicine

Discover the cutting-edge world of biopharmaceuticals and how it's reshaping healthcare. From advanced therapies to life-changing drugs, explore the dynamic landscape of biopharma products.

Mapping the Future of Biopharma: Insights from McKinsey's Helix Report

Explore the McKinsey Helix Report and discover insights into the future success of the biopharmaceutical industry.

BMY Stock: Precision Medicine & Immunotherapy in Cancer Treatment

Explore how Bristol-Myers Squibb pioneers cancer treatment using precision medicine & immunotherapy for improved patient outcomes and survival rates.

Daily Stock Watch: Is Kymera a Buy?

Biotech outfit Kymera Therapeutics (NASDAQ: KYMR) is heading upwards on the back of positive clinical trial news. But is KYMR stock a good investment?

Is Ginkgo Bioworks Stock A Good Buy?

The Ginkgo Bioworks (NYSE: DNA) share price is beaten down this year. We look at whether DNA Stock is a good buy.